Search

Displaying results 4091 - 4100 of 5419 in total
  1. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used treat certain types of acut...

  2. Drug

    PI-166

    go.drugbank.com/drugs/DB05859
    Experimental

    PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.

  3. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a ...

  4. Drug

    PPL-100

    go.drugbank.com/drugs/DB05961
    Investigational

  5. Drug

    Archexin

    go.drugbank.com/drugs/DB05971
    Investigational

  6. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). The investigational drug was under investigation in clinical trial NCT00473...

  7. Drug

    XMT-1001

    go.drugbank.com/drugs/DB06069
    Investigational

    XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, ...

  8. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  9. Drug

    PRLX 93936

    go.drugbank.com/drugs/DB06098
    Investigational

    PRLX 93936 is selectively toxic to cancer cells.

  10. Drug

    Eldelumab

    go.drugbank.com/drugs/DB06116
    Investigational

    MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.